ArticleAnnals of surgical oncology2026
Platinum-Based Chemotherapy Versus Secondary Cytoreductive Surgery Before Olaparib Maintenance Therapy for 259 Patients with BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer: A Multicenter Retrospective Study: Comparative Effectiveness and Survival Outcomes Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of secondary cytoreduction surgery (SeCRS) followed by olaparib maintenance therapy for recurrent ovarian cancer has not been clearly demonstrated. This study aimed to evaluate the role of SeCRS combined with olaparib for patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer.
methodsThis multi-center retrospective study analyzed patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer treated between July 2015 and August 2024. Overall survival (OS) and progression-free survival (PFS) were used to measure treatment effectiveness. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0.
resultsAmong 259 patients, 124 were treated with SeCRS followed by platinum-based chemotherapy (the surgery group), and 135 were treated with platinum-based chemotherapy alone (the chemotherapy group). All patients received olaparib tablets until disease progression. The median PFS in the surgery group was significantly longer than in the chemotherapy group (27.2 vs. 18.2 months; hazard ratio [HR], 0.46; 95 % confidence interval [CI], 0.35-0.62; p < 0.001). The median OS was significantly longer in the surgery group than in the chemotherapy group (68.1 vs. 50.5 months; HR, 0.57; 95 % CI 0.42-0.78; p < 0.001). The incidence and severity grades of adverse events did not differ significantly between the two groups.
conclusionThe findings of this study suggest that SeCRS followed by platinum-based chemotherapy and olaparib maintenance therapy results in longer OS and PFS than platinum-based chemotherapy followed by olaparib maintenance therapy alone for patients with BRCA-mutated platinum-sensitive recurrent ovarian cancer.
Indexed as
Identifiers
41483277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.